Frederick M. Hudson has served as a member of the Board since 2010. Mr. Hudson retired as a partner in charge of the healthcare audit practice for the Washington-Baltimore business unit of the accounting firm of KPMG, LLP, on January 1, 2006, after a 37-year career with the firm. He currently serves on the Board of Financial Administration of the Catholic Archdiocese of Baltimore and the Board of Trustees of the Maryland Historical Society. Mr. Hudson chairs the Audit Committee of the Board of Directors for each of the following: Paradigm Management Services (a provider of catastrophic care services), Woodhaven Holding Corporation, d/b/a Remedi Senior Care (an institutional pharmacy service provider), GBMC Healthcare, Inc., and its affiliate, the Greater Baltimore Medical Center, and Vicor Technologies, Inc. He is also a director of Maxim HealthCare Services, Inc. Mr. Hudson is a graduate of Loyola University Maryland.
Jack A. Khattar is the founder of Supernus Pharmaceuticals and has served as President and Chief Executive Officer and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including Board Member, President, and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Mr. Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA, a drug delivery company that is currently a division of Cephalon. At CIMA, he was also responsible for business development, including the licensing of CIMA's technologies, corporate alliances, and strategic planning.
Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe, and the Middle East. He is currently a director of Rockville Economic Development Inc. Mr. Khattar earned his degrees in marketing, with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.
Charles W. Newhall, III has served as a member of the Board since 2005. In 1977, Mr. Newhall co-founded New Enterprise Associates, Inc. (NEA), a venture capital firm that focuses on the medical and life sciences and information technology industries. Mr. Newhall has served as a director of over 40 venture-backed companies. He started several healthcare information technology companies, including PatientKeeper, TargetRx, and LifeMetrix. Some of his current Board memberships include Vitae Pharmaceuticals, TargetRx, Sensors for Medicine and Science, and BrainCells Inc. In 1986, he founded the Mid-Atlantic Venture Capital Association (MAVA), which now has over 80 venture capital firms that are members, and is one of the most active regional venture associations in the country. He is now Chairman Emeritus of MAVA. Before NEA, Mr. Newhall was a Vice President of T. Rowe Price.
Mr. Newhall served in Vietnam commanding an independent platoon, including an initial reconnaissance of Hamburger Hill. His decorations include the Silver Star and Bronze Star V (1st OLC). He earned an honors degree in English from the University of Pennsylvania and an MBA from Harvard Business School.
John M. Siebert, PhD has served as a member of the Board since 2011. Dr. Siebert has more than 30 years of experience in the pharmaceutical industry. Since 2009, he has been Chairman and CEO of Compan Pharmaceuticals, LLC, a veterinary specialty company. Prior to his positions at Compan Pharmaceuticals, LLC, Dr. Siebert served as Chairman and CEO of CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company; and President and CEO of CIMA Labs, Inc., an innovative oral drug delivery company. Dr. Siebert began his career at Proctor & Gamble. He currently chairs the Audit Committee of the Board of Directors of both Primus Pharmaceuticals Inc. and Aradigm.
Georges Gemayel, PhD, was appointed as a director of the Company effective March 23, 2015. Dr. Gemayel has more than 25 years of experience in the pharmaceutical industry, including management and executive positions spanning the United States, Europe and the Middle East and mostly at Roche, at Genzyme and Altus. Dr. Gemayel currently serves as Chairman of the Board of Directors of Oxthera, Enterome and Orphazyme, all privately held companies, and as Director of Raptor Pharmaceuticals (a NASDAQ listed company) and Dimension Therapeutics (a privately held company). He was previously a director of Adolor Corporation, FoldRx, Prosensa, Epitherapeutics, Syndexa, Vascular Magnetics and NPS Pharmaceuticals.